Reference : ACTH silent adenoma shrinking under cabergoline.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
ACTH silent adenoma shrinking under cabergoline.
Petrossians, Patrick [Centre Hospitalier Universitaire de Liège - CHU > > Endocrinologie clinique >]
Ronci, N. [ > > ]
Valdes Socin, Hernan Gonzalo [Centre Hospitalier Universitaire de Liège - CHU > > Endocrinologie clinique >]
Kalife, A. [ > > ]
Stevenaert, Achille [Centre Hospitalier Universitaire de Liège - CHU > > Neurochirurgie >]
Bloch, B. [ > > ]
Tabarin, A. [ > > ]
Beckers, Albert [Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie >]
European Journal of Endocrinology
BioScientifica Ltd
Yes (verified by ORBi)
United Kingdom
[en] Adenoma/chemistry/drug therapy/secretion ; Adrenocorticotropic Hormone/secretion ; Aged ; Antineoplastic Agents/therapeutic use ; Autoradiography ; Ergolines/therapeutic use ; Humans ; In Situ Hybridization ; Male ; Neoplasm Recurrence, Local ; Pituitary Neoplasms/chemistry/drug therapy/secretion ; Prolactinoma/chemistry ; RNA, Messenger/analysis ; Receptors, Dopamine D2/analysis/genetics
[en] OBJECTIVES: The authors present a case report that proposes the use of cabergoline treatment in silent ACTH adenoma, an unusual member of the heterogeneous group of the so-called clinically non-functioning pituitary adenomas. DESIGN: Following the clinical and radiological improvement of a recurrent silent ACTH adenoma in a 77-year-old patient treated with cabergoline (0.5 mg every 2 days for 2 years), in vitro studies of the original tumor were performed. METHODS: The original tumor from the patient was studied by in situ hybridization and dopamine D2 receptor autoradiography. It was compared with four macroprolactinomas and two macroadenomas from patients with Cushing's disease. RESULTS: The D2 receptor mRNA signal of the reported case was intense and of the same order of magnitude as that observed in control prolactinomas. Dopamine D2 receptor autoradiography was twice that of control corticotroph adenomas and was close to that observed in prolactinomas. CONCLUSIONS: This is the first description of an in vivo shrinkage of an ACTH silent adenoma under cabergoline. We demonstrate in vitro, the presence of D2 receptors in the primitive tumor in concentrations similar to those found in control prolactinomas. These results suggest that therapeutic trials with cabergoline might be undertaken in recurring cases of ACTH silent tumors and more generally, non-functioning pituitary adenomas.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Open access
ACTH silent adenoma shrinking under cabergoline_2001.pdfPublisher postprint869.18 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.